These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 5166031

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: effect of culture duration on therapeutic efficacy.
    Cheever MA, Greenberg PD, Fefer A.
    J Natl Cancer Inst; 1981 Jul; 67(1):169-73. PubMed ID: 6942187
    [Abstract] [Full Text] [Related]

  • 43. Total lymphoid irradiation (TLI) and allogeneic marrow transplantation for enzyme replacement therapy and immunotherapy of leukemia in mice.
    Slavin S, Yatziv S, Weiss L, Morecki S, Abeliuk P, Fuks Z.
    Transplant Proc; 1981 Mar; 13(1 Pt 1):439-42. PubMed ID: 7022868
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Alloimmunization: induction of antileukemic reactivity without modification of anti-host reactivity in H-2-compatible mice.
    Truitt RL, Bortin MM, Rimm AA.
    Transplant Proc; 1980 Mar; 12(1):143-6. PubMed ID: 6966095
    [Abstract] [Full Text] [Related]

  • 47. Modification of tumor cell antigen.
    Kobayashi H.
    Prog Clin Biol Res; 1983 Mar; 132E():305-14. PubMed ID: 6316367
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Elimination of L5178Y cells from tumor-dormant DBA/2 mice by specific active immunotherapy.
    Marsili MA, Robinson MK, Truitt GA, Wheelock EF.
    Cancer Res; 1983 Jan; 43(1):15-21. PubMed ID: 6600159
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Immunotherapy and chemotherapy of Moloney sarcoma virus-induced tumors in mice.
    Fefer A.
    Cancer Res; 1969 Dec; 29(12):2177-83. PubMed ID: 5369675
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Detection of early and delayed antitumor effects following curative adoptive chemoimmunotherapy of established leukemia.
    Greenberg PD, Cheever MA, Fefer A.
    Cancer Res; 1980 Dec; 40(12):4428-32. PubMed ID: 7438073
    [Abstract] [Full Text] [Related]

  • 56. Extraction of leukemia associated antigen (LAA) and active specific immunization with LAA in acute leukemia.
    Ezaki K.
    Nagoya J Med Sci; 1980 Mar; 42(3-4):55-68. PubMed ID: 7383145
    [No Abstract] [Full Text] [Related]

  • 57. T cell tolerance in moloney-murine leukemia virus (M-MuLV) carrier mice: low cytotoxic T lymphocyte precursor frequency and absence of suppressor T cells in carrier mice with Moloney-murine sarcoma (M-MSV)-induced tumors.
    Collavo D, Ronchese F, Zanovello P, Biasi G, Chieco-Bianchi L.
    J Immunol; 1982 Feb; 128(2):774-9. PubMed ID: 6459385
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.